Citadel Advisors’s iTeos Therapeutics ITOS Stock Holding History

Citadel Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150,700	Closed	-$1.5M	–	13429
2025 Q2	$1.5M	Buy	150,700 +73,900	+96%	+$595K	﹤0.01%	6253
2025 Q1	$458K	Sell	76,800 -117,000	-60%	-$859K	﹤0.01%	8660
2024 Q4	$1.49M	Buy	193,800 +64,300	+50%	+$552K	﹤0.01%	6246
2024 Q3	$1.32M	Buy	129,500 +70,200	+118%	+$1.07M	﹤0.01%	6296
2024 Q2	$880K	Buy	59,300 +27,100	+84%	+$388K	﹤0.01%	6853
2024 Q1	$439K	Sell	32,200 -25,800	-44%	-$281K	﹤0.01%	8673
2023 Q4	$635K	Buy	58,000 +31,000	+115%	+$307K	﹤0.01%	7600
2023 Q3	$296K	Buy	27,000 +8,900	+49%	+$114K	﹤0.01%	9207
2023 Q2	$240K	Buy	18,100 +3,300	+22%	+$47.1K	﹤0.01%	9502
2023 Q1	$201K	Buy	14,800 +1,500	+11%	+$26.9K	﹤0.01%	10172
2022 Q4	$260K	Buy	+13,300	New	+$260K	﹤0.01%	9620

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citadel Advisors's ITOS Position: Q3 2025 in Review

Citadel Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 94,256 shares — an estimated $940K sold.

Citadel Advisors first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $46.5M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Citadel Advisors reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 94,256 iTeos Therapeutics shares in Q3 2025, an estimated $940K.
Citadel Advisors first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
Citadel Advisors's iTeos Therapeutics position peaked at $46.5M in Q4 2021.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.